AWARD NUMBER: W81XWH-17-1-0665

TITLE: Prevention of Post-Traumatic Contractures with Ketotifen II (PERK II)

PRINCIPAL INVESTIGATOR: Kevin A. Hildebrand

CONTRACTING ORGANIZATION: Governors of the University of Calgary

REPORT DATE: OCTOBER 2022

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
OCTOBER 2022	Annual	30SEPT2021 - 29SEPT2022

4. TITLE AND SUBTITLE
Prevention of Post-Traumatic Contractures with Ketotifen

II (PERK II)

5a. CONTRACT NUMBER
W81XWH-17-1-0665

5b. GRANT NUMBER
OR160026

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)
Kevin A. Hildebrand

E-Mail: hildebrk@ucalgary.ca

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
Governors of the University of Calgary
2500 University Drive NW
Calgary, Alberta CANADA
T2N 1N4

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT
278 participants recruited by September 28, 2022. With 15 sites able to screen/recruit participants, we are maintaining an average of 12 participants enrolled per month. After receiving a no cost extension for the year 2022-2023, we are planning on maintaining recruitment efforts and covering operational logistics needed to reach the highest sample possible. Trial Steering Committee is working on a protocol amendment, proposing a sample size recalculation that would result in an attainable sample size that would still produce results originally outlined for the trial. Submission of amendment is scheduled for Q1 of year 6.

Monthly Trial Management Group meetings continue to be held with site coordinators to maintain awareness of ongoing trial activities. Quarterly Trial Steering Committees were held, which informed TMG meetings on ways to improve and maintain enrollment efforts. Finally, three Data Monitoring Committee meetings (one closed and one open) were held, resulting in unbiased oversight of safety and efficacy points of the trial. DMC members recommended the trial to continue as planned.

15. SUBJECT TERMS
Randomized Clinical Trial; Multicenter; Placebo; Ketotifen; Contractures; Post-traumatic; Elbow fractures or dislocations; Surgery; Range of motion; Disability Arm Shoulder Hand; Oxford Elbow Score; Pain Catastrophizing Scale.

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRDC
Unclassified	Unclassified	Unclassified	Unclassified	44	19b. TELEPHONE NUMBER *(include area code)*

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18

Table of Contents

1. **INTRODUCTION:** Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.

This proposal pertains to the FY16 PRORP CTA Focus Area on Surgical Care – Extremity Fractures. This research optimizes patient outcomes through prevention of post-traumatic joint contractures following fractures. We are conducting a multicenter, multidose randomized clinical trial comparing Ketotifen fumarate to a Lactose placebo started within 7 days of elbow fractures or dislocations. The primary outcome measure is elbow extension-flexion arc range of motion 12 weeks after randomization. Secondary outcome measures are range of motion at other selected time points and patient reported outcome measures at these time points and 12 weeks.

2. **KEYWORDS:** Provide a brief list of keywords (limit to 20 words).

Randomized Clinical Trial; Multicenter; Placebo; Ketotifen; Contractures; Post-traumatic; Elbow fractures or dislocations; Surgery; Range of motion; Disability Arm Shoulder Hand; Oxford Elbow Score; Pain Catastrophizing Scale

3. **ACCOMPLISHMENTS:** The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction.

What were the major goals of the project?

Major Task 1: Complete Clinical Trial Development Award – this was OR140142

Major Task 2: Phase III RCT Implementation

Major Task 3: Study Performance

Major Task 4: Knowledge Translation

What was accomplished under these goals?

Major Task 1: Complete CTDA OR140142

1. Major Activities:
    a. Regulatory Compliance
    b. Core Study Functions
    c. Recruiting Sites
2. Specific Objectives:
    a. Complete contract negotiations with recruiting sites.
    b. Obtain Ethics Internal Review Board and Department of Defense Human Research Protection Office (HRPO) approval for 17 participating sites.

3. Results:
    a. Site initiation visit was completed for the last site in plans for activation, McGill University. Unfortunately, site withdrew from activation citing limitations at the staff and operations level. **See pages 13 - 17.**

Major Task 2: Phase III RCT Implementation

1. Major Activities:
    a. Organizational Transitions
    b. Site Initiations
    c. Organizing Screening, Enrollment and Randomization Procedures
2. Specific Objectives:
    a. Start at Calgary Sites
    b. Site roll out outside of Calgary
3. Results:
    a. 15 active sites across North America continue screening/enrollment procedures. As a result, 278 participants have been recruited and randomized into the clinical trial by September 29, 2022. Appendix reflects 278 participants randomized by the end of the reporting period. **See appendices page 18 – 26**.

Major Task 3: Study Performance

1. Major Activities:
    a. Trial Committees
    b. Support Organizations
2. Specific Objectives:
    a. Three performance committees meetings
    b. Regular meetings with Core facilities – EPICORE, CIPAC, BARL
3. Results:
    a. Monthly Trial Management Group (TMG) meetings were held during this reporting period. Minutes to latest TMG meetings are attached. **See appendices pages 27 - 35**.
    b. Trial Steering Committee (TSC) meetings were held during this reporting period. Minutes to latest TSC Meeting are attached. **See appendices pages 36 – 38**.
    c. Data Monitoring Committee closed and open meetings were held. Response letters from DMC members are attached. **See appendices pages 39 – 40**.

Major Task 4: Knowledge Translation

1. Major Activities:
    a. Publications/Meetings
    b. Trial Results
    c. Site Engagement and Updates
2. Specific Objectives
    a. Trial protocol manuscript, Specialty meetings abstracts and attendance
    b. Trial results – Primary paper, secondary papers, presentations specialty societies
    c. Site engagement
3. Results
    a. Monthly PERK 2 newsletter continued through the year. **See appendices pages 41 –43.**

What opportunities for training and professional development has the project provided?

Our trial coordinator, Gerardo Duque, wrote and passed his SOCRA Certified Clinical Research Professional (CCRP) certification exam. This is a recognized certification supporting the development and excellence of active clinical trial staff. **See appendices page 44**.

How were the results disseminated to communities of interest?

Nothing to report.

What do you plan to do during the next reporting period to accomplish the goals?

Our objective for year 6 is to continue enrollment and randomization procedures with 15 active sites, maintaining our current average of 12 new participants per month. Further, we will continuing our monthly TMG and quarterly TSC meetings to inform next steps need for continued success with the trial. A DMC closed meeting is scheduled to be held on December 2 (Y6, Q1) to maintain proper oversight of safety and efficacy endpoints. Finally, continuing manuscript and presentation development, with eyes set in further literature development efforts towards Year 6, Quarter 2.

4. **IMPACT:** Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:

What was the impact on the development of the principal discipline(s) of the project?

Nothing to report.

What was the impact on other disciplines?

Nothing to Report

What was the impact on technology transfer?

Nothing to Report

What was the impact on society beyond science and technology?

Nothing to Report

5. **CHANGES/PROBLEMS:** The PD/PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, "Nothing to Report," if applicable:

Changes in approach and reasons for change

Trial Steering Committee is working on a protocol amendment, proposing a sample size recalculation that would result in an attainable sample size that would still produce results originally outlined for the trial. Submission of amendment is scheduled for Q1 of year 6.

Actual or anticipated problems or delays and actions or plans to resolve them

We do not expect any anticipated problems or delays during this year. However, as discussed with our DoD Scientific Officer and Grant Officers, we will be requesting an advanced payment and further no cost extension next year to cover for the year follow up needed for every patient enrolled during Year 6 (2022 – 2023).

Changes that had a significant impact on expenditures

Nothing to report

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Nothing to report

Significant changes in use or care of human subjects

Nothing to report

Significant changes in use or care of vertebrate animals

Nothing to report

Significant changes in use of biohazards and/or select agents

Nothing to report

6. PRODUCTS

- **Publications, conference papers, and presentations**

Journal publications.

Nothing to report

Books or other non-periodical, one-time publications.

Nothing to report

Other publications, conference papers and presentations.

Nothing to report

- **Website(s) or other Internet site(s)**

Nothing to report

- **Technologies or techniques**

Nothing to report

- **Inventions, patent applications, and/or licenses**

Nothing to report

- **Other Products**

Nothing to report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Name:	Kevin Hildebrand
Project Role:	Principal Investigator
Research Identifier:	orcid.org/0000-0001-8786-9021
Nearest Person Month worked:	12
Contribution to Project:	Overall management. Writing grants, study design. Recruiting sites. Obtaining data management, medication partners.
Funding Support:	Department of Surgery University of Calgary
Name:	Gerardo Duque
Project Role:	Research Coordinator
Research Identifier:	None
Nearest Person Month worked:	12
Contribution to Project:	Regulatory application (IND, HRPO, Health Canada). Database Development and quality assurance. Case report forms and consent writing. Screening, recruitment, randomization, and participant follow-ups. Contracts. Institutional Review Board processing.
Funding Support:	Department of Defense.
Name:	Taylor Stranaghan
Project Role:	Clinical Research Assistant
Research Identifier:	None
Nearest Person Month Worked:	6
Contribution to Project:	Clinical trial implementation and ongoing development. Screening, recruitment, randomization, and participant follow-ups. Case report form development. Institutional Review Board processing.
Funding Support:	Department of Defense
Name:	Isabella Salazar
Project Role:	Clinical Research Assistant
Research Identifier:	None
Nearest Person Month Worked:	6
Contribution to Project:	Clinical trial implementation and ongoing development. Screening, recruitment, randomization, and participant follow-ups. Case report form development. Institutional Review Board processing.
Funding Support:	Department of Defense

Funding Support:	Department of Defense
Name:	Tolulope Sajobi
Project Role:	Trial Statistician
Research Identifier:	orcid.org/0000-0002-5696-5552
Nearest Person Month worked:	1
Contribution to Project:	Statistical support. Recruitment and co-supervise PhD student.
Funding Support:	Department of Community Health Sciences, University of Calgary
Name:	Ayoola Ademola
Project Role:	PhD Graduate Student
Research Identifier:	None
Nearest Person Month worked:	1
Contribution to Project:	Statistical support
Funding Support:	Department of Defense

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Taylor Stranaghan, our research assistant for the first 6 months of this reporting period, transitioned out of this .5 FTE position. We filled this position with Isabella Salazar. Isabella has successfully covered the last 6 months of this reporting period.

What other organizations were involved as partners?

Organization Name:	Bay Area Research Logistics
Location:	Hamilton, ON, CANADA
Contribution:	Sourcing Ketotifen, Lactose Placebo, manufacturing and distribution study medication
Organization Name:	EPICORE Centre
Location:	University of Alberta, Edmonton, AB, CANADA
Contribution:	Development of RedCap Electronic Data Capture, Randomization process (Drug Tracking System), Project management, servers to support study
Organization Name:	Calgary Image Processing and Analysis Centre
Location:	Calgary, AB, CANADA
Contribution:	Archiving and analysis centre for radiographic evaluation of fracture healing
Organization Name:	Alberta Health Services
Location:	Peter Lougheed Centre, Calgary, AB, CANADA
Contribution:	Office space, computer support, clinic space for recruitment and follow up of participants

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS: For collaborative awards, independent reports are required from BOTH the Initiating Principal Investigator (PI) and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to **https://ers.amedd.army.mil** for each unique award.

QUAD CHARTS: If applicable, the Quad Chart (available on https://www.usamraa.army.mil) should be updated and submitted with attachments. **See appendices page 14**.

9. APPENDICES:

Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.

Prevention of Post-Traumatic Contractures with Ketotifen II (PERK II)
0R160026
W81XWH-17-1-0665

PI: Kevin A. Hildebrand **Org:** Governors of the University of Calgary **Award Amount:** $2,440,796

Study/Product Aim(s)

- Major Task I: Complete Clinical Trial Development Award – CTDA (OR140142)
- Major Task 2: Phase III RCT Implementation
- Major Task 3: Study Performance
- Major task 4: Knowledge Translation

Approach

PERK II is a multicenter RCT led from Calgary, CANADA with US centers included. Completing the CTDA will have the infrastructure in place to perform the RCT. This trial will compare 2 different doses of ketotifen fumarate to a lactose placebo in preventing post-traumatic contractures following elbow injuries that require an operation. The medication is randomized, while operation requirement is not.

PERK 2

278 participants recruited by September 28, 2022. With 15 sites able to screen/recruit participants, we are maintaining an average of 12 participants enrolled per month. After receiving a no cost extension for the year 2022-2023, we are planning on maintaining recruitment efforts and covering operational logistics needed to reach the highest sample possible. Trial Steering Committee is working on a protocol amendment, proposing a sample size recalculation that would result in an attainable sample size that would still produce results originally outlined for the trial. Submission of amendment is scheduled for Q1 of year 6.

Timeline and Cost

Activities CY	17	18	19	20	21	22
Complete CTDA						
Phase III RCT Implementation						
Study Performance						
Knowledge Translation						
Estimated Budget ($K)	**$154**	**$638**	**$704**	**$536**	**$408**	**$0**

Updated: (September 29th, 2022)

Goals/Milestones
CY17 Goal – Complete CTDA
☑IND Approval
✓ Database and Medication Manufacture Development
CY18 Goals – Regulatory/IRB/Contracts
✓ PLC completed all steps
✓ Other sites in progress
CY19 Goal – Continue recruitment
☐Complete CTDA
✓ Recruit first participant
✓ Add other sites
CY20 Goal – Continue recruitment, follow up
☐ All sites recruiting

Comments/Challenges/Issues/Concerns
1 year no cost extension granted to continue enrollment and follow ups on year 5. 15/17 sites currently screening/recruiting.

Budget Expenditure to Date
Projected Expenditure: $2,440,795
Actual Expenditure: $1,268,749

From:	Mancha-Wright, Sandra G CIV USARMY FUTURES COMMAND (USA)
To:	"edward.harvey@mcgill.ca"; "ejharvey@videotron.ca"; "harvey.ej@gmail.com"
Cc:	Gerardo Duque; Harris, Tracey E CIV USARMY HQ USAMRDC (USA); Tiago Lier; Kevin A. Hildebrand; Grenier, Kenneth E CIV USARMY USAMRAA (USA); Yadav, Prem CIV USARMY CDMRP (USA); "mary.amedeo@muhc.mcgill.ca"; Odam, Kimberly L CIV USARMY HQ USAMRDC (USA); Kline, Andrea J CIV USARMY HQ USAMRDC (USA); Eaton, Karen M CTR USARMY HQ USAMRDC (USA); Ofosu-Appiah, Nina Marie M CTR USARMY FUTURES COMMAND (USA); Mendoza, Jessica L CIV USARMY HQ USAMRDC (USA); Mancha-Wright, Sandra G CIV USARMY FUTURES COMMAND (USA)
Subject:	A-20465.n, HRPO Protocol Closure Memorandum (Proposal Log Number OR160026, Award Number W81XWH-17-1-0665) (UNCLASSIFIED)
Date:	Thursday, March 24, 2022 1:02:55 PM

[EXTERNAL]

CLASSIFICATION: UNCLASSIFIED

SUBJECT: HRPO Closure for the Protocol, “PrEvention of Post-Traumatic Joint ContractuRes with Ketotifen 2 (PERK 2),” Submitted by Edward J. Harvey, MD, McGill University Health Centre, Montreal General Hospital, Montreal, Canada, in Support of the Proposal, “PrEvention of Post-Traumatic Joint ContractuRes with Ketotifen II (PERK II),” Submitted by Kevin A. Hildebrand, MD, University of Calgary - Health Research Innovation Centre, Calgary, Alberta, Canada, Proposal Log Number OR160026, Award Number W81XWH-17-1-0665, HRPO Log Number A-20465.n

1. The U.S. Army Medical Research and Development Command (USAMRDC), Office of Research Protections (ORP), Human Research Protection Office (HRPO) initially approved the greater than minimal risk study on 20 August 2021.

2. The McGill University Health Centre Research Ethics Board documentation acknowledging closure of this study dated 18 March 2022 was received by the USAMRDC ORP HRPO on 21 March 2022.

3. The USAMRDC ORP HRPO also received and reviewed continuing review documents for the 2022-2023 review period. The submitted documents were reviewed and found to be acceptable

4. No further review of this protocol will be conducted and the HRPO will close the file.

5. The HRPO point of contact for this study is Nina Ofosu-Appiah, Human Subjects Protection Scientist, at 301-619-7550, DSN 343-7550, or ninamarie.m.ofosu-appiah.ctr@mail.mil

SANDRA G. MANCHA-WRIGHT, BS
Chief, Research Administrative Support
Human Research Protection Office

Centre universitaire de santé McGill | McGill University Health Centre

Closure of research project - Harmonized

Protocol title: **Prevention of Post-traumatic Contractures with Ketotifen 2**

Project number(s): **2020-5501**

Nagano identifier: **PERK 2**

Principal investigator: **Edward J. Harvey**

Project's REB approbation date: **2021-03-03**

Form: **F10H-92629**

First submit date: **2022-03-16**

Last submit date: **2022-03-16**

Form status: **Form closed**

Administration - REB

1. **MUHC REB Panel & Co-chair(s):**
   Clinical Trials 2 (CT2)
   Co-chairs: Bertrand Lebouché, Sonya Page
   reb.ct2@muhc.mcgill.ca

2. **REB Decision:**
   Acknowledgement of receipt

3. **Date of the REB final decision & signature**
   2022-03-18
   Signature

Sheldon Levy
MUHC REB Coordinator
for MUHC REB Co-chair mentioned above
2022-03-18 11:34

General Information

1. **Please indicate for which institution you wish to declare the project closure.**
   For your institution only

2. **Indicate the name of the Principal Investigator in our institution (MUHC)**

Harvey, Edward J.

From which department is the principal investigator?

Orthopedic Surgery

Closure (site-specific)

1. **Date the study was complete:**

2022-03-14

2. **Indicate the reason for the permanent closure (or cancellation) of the project:**

Other

Specify the reason

Insufficient human resources at our site to dedicate to this study.

3. **Please indicate the type of "participants" implicated in your research project**

Individuals

Number of participants to recruit initially for your institution according to the protocol and / or the contract:

40

Number of participants that have been recruited to the study (have signed a consent form):

0

Number of minors:

0

Number of incompetent adults:

0

Were any of these participants excluded based on the inclusion or exclusion criteria (screen fails)?

No

Have any of these participants been withdrawn during the project?

No

Did any of the participants stop participating in the project?

No

Did any participants die while participating in the project?

No

Number of participants whose participation has not yet ended (in follow-up and on treatment):

0

Number of participants who have completed all study procedures (follow-up completed):

0

4. **In terms of what you are responsible to report, over the past year, relative to the situation at the time of the last REB renewal (or initial approval):**

Have there been any unreported changes to the REB affecting the study documents?

No

Were there unanticipated problems, serious adverse reactions, major deviations or other events or information altering the ethical acceptability or balance between risks and benefits of the project that were not reported to the REB?

No

Were there any temporary interruptions to the project?

No

Have the results of the project been submitted for publication, presented or published?

No

Should the REB be notified of a conflict of interest situation (of any kind) affecting one or more members of the research team, that was not reported at the time of the last approval of the project?

No

Has there been an allegation related to a breach in ethical compliance (eg: complaint from a participant, non-compliance with rules relating to ethics or integrity) concerning one or more researchers?

No

Does the sponsor require the submission of minor deviations from the protocol or other report that does not identify any impact on participant safety?

No

5. **Summary of research project findings**

While this study has not been initiated at the Montreal General, it is ongoing at other sites, however, it is still too early to provide project findings.

6. **What is the plan for the dissemination of the research results?**

Publication(s) and presentations of findings.

7. **Amounts received for this project?**

Yes

Therefore, are you asking for a closure of the project account in the finance department?

Non

Signature

Answer of: Amedeo, Mary

1. **I certify that the information provided on this form is correct.**

Mary Amedeo
2022-03-16 09:28

Data Exports, Reports, and Stats

Number of results returned: 278

Total number of records queried: 7,058

('records' = total available data across all designated events)

Randomized Subjects

Screening ID screen_id	**Event Name** redcap_event_name	**Repeat Instrument** redcap_repeat_instrument	**Repeat Instance** redcap_repeat_instance	**Data Access Group** redcap_data_access_group	**BOTTLE ID** rand_group	**Date of randomization** rand_dt
5358-4 (Participant ID 01-001)	Screening/ Randomization			Peter Lougheed Centre	10008	2019-06-29
5362-2 (Participant ID 05-001)	Screening/ Randomization			South Health Campus	10072	2019-07-02
5362-13 (Participant ID 05-002)	Screening/ Randomization			South Health Campus	10049	2019-07-26
5358-5 (Participant ID 01-002)	Screening/ Randomization			Peter Lougheed Centre	10001	2019-07-27
5358-47 (Participant ID 01-003)	Screening/ Randomization			Peter Lougheed Centre	10006	2019-08-29
5362-31 (Participant ID 05-003)	Screening/ Randomization			South Health Campus	10073	2019-09-03
5362-34 (Participant ID 05-004)	Screening/ Randomization			South Health Campus	10066	2019-09-04
5358-56 (Participant ID 01-004)	Screening/ Randomization			Peter Lougheed Centre	10020	2019-09-11
5362-39 (Participant ID 05-005)	Screening/ Randomization			South Health Campus	10050	2019-09-17
5358-70 (Participant ID 01-005)	Screening/ Randomization			Peter Lougheed Centre	10012	2019-10-11
5362-46 (Participant ID 05-006)	Screening/ Randomization			South Health Campus	10068	2019-10-15
5370-1 (Participant ID 13-001)	Screening/ Randomization			Sturgeon Community Hospital	10113	2019-10-16
5370-3 (Participant ID 13-002)	Screening/ Randomization			Sturgeon Community Hospital	10107	2019-10-28
5370-4 (Participant ID 13-003)	Screening/ Randomization			Sturgeon Community Hospital	10101	2019-10-29
5362-56 (Participant ID 05-007)	Screening/ Randomization			South Health Campus	10053	2019-11-05
5358-77 (Participant ID 01-006)	Screening/ Randomization			Peter Lougheed Centre	10009	2019-11-08
5370-6 (Participant ID 13-004)	Screening/ Randomization			Sturgeon Community Hospital	10102	2019-11-20
5358-87 (Participant ID 01-007)	Screening/ Randomization			Peter Lougheed Centre	10011	2019-11-29
5370-8 (Participant ID 13-005)	Screening/ Randomization			Sturgeon Community Hospital	10108	2019-12-04
5360-1 (Participant ID 03-001)	Screening/ Randomization			Foothills Medical Centre	10037	2019-12-06
5360-3 (Participant ID 03-002)	Screening/ Randomization			Foothills Medical Centre	10036	2019-12-09
5362-71 (Participant ID 05-008)	Screening/ Randomization			South Health Campus	10070	2019-12-10
5362-72 (Participant ID 05-009)	Screening/ Randomization			South Health Campus	10079	2019-12-10
5358-93 (Participant ID 01-008)	Screening/ Randomization			Peter Lougheed Centre	10030	2019-12-20
5360-5 (Participant ID 03-003)	Screening/ Randomization			Foothills Medical Centre	10028	2019-12-23
5362-81 (Participant ID 05-010)	Screening/ Randomization			South Health Campus	10056	2019-12-26
5368-1 (Participant ID 11-001)	Screening/ Randomization			The Ottawa Hospital, Civic Campus	10155	2020-01-10
5358-103 (Participant ID 01-009)	Screening/ Randomization			Peter Lougheed Centre	10203	2020-01-23
5358-104 (Participant ID 01-010)	Screening/ Randomization			Peter Lougheed Centre	10197	2020-01-24
5362-92 (Participant ID 05-011)	Screening/ Randomization			South Health Campus	10233	2020-01-27

Screening ID screen_id	**Event Name** redcap_event_name	**Repeat Instrument** redcap_repeat_instrument	**Repeat Instance** redcap_repeat_instance	**Data Access Group** redcap_data_access_group	**BOTTLE ID** rand_group	**Date of randomization** rand_dt
5362-94 (Participant ID 05-012)	Screening/ Randomization			South Health Campus	10239	2020-02-04
5360-10 (Participant ID 03-004)	Screening/ Randomization			Foothills Medical Centre	10219	2020-02-05
5359-10 (Participant ID 02-001)	Screening/ Randomization			University of Maryland Medical Center	10131	2020-02-07
5369-1 (Participant ID 12-001)	Screening/ Randomization			The Ottawa Hospital, General Campus	10185	2020-02-11
5360-12 (Participant ID 03-005)	Screening/ Randomization			Foothills Medical Centre	10209	2020-02-12
5370-11 (Participant ID 13-006)	Screening/ Randomization			Sturgeon Community Hospital	10103	2020-02-17
5370-12 (Participant ID 13-007)	Screening/ Randomization			Sturgeon Community Hospital	10114	2020-02-21
5374-1 (Participant ID 17-001)	Screening/ Randomization			University of Vermont Medical Center	10245	2020-02-27
5358-120 (Participant ID 01-011)	Screening/ Randomization			Peter Lougheed Centre	10204	2020-03-02
5362-104 (Participant ID 05-013)	Screening/ Randomization			South Health Campus	10227	2020-03-02
5359-14 (Participant ID 02-002)	Screening/ Randomization			University of Maryland Medical Center	10125	2020-03-03
5358-122 (Participant ID 01-012)	Screening/ Randomization			Peter Lougheed Centre	10198	2020-03-05
5358-125 (Participant ID 01-013)	Screening/ Randomization			Peter Lougheed Centre	10191	2020-03-12
5374-2 (Participant ID 17-002)	Screening/ Randomization			University of Vermont Medical Center	10251	2020-03-16
5358-126 (Participant ID 01-014)	Screening/ Randomization			Peter Lougheed Centre	10192	2020-06-30
5362-108 (Participant ID 05-014)	Screening/ Randomization			South Health Campus	10234	2020-07-17
5374-3 (Participant ID 17-003)	Screening/ Randomization			University of Vermont Medical Center	10257	2020-07-27
5368-16 (Participant ID 11-002)	Screening/ Randomization			The Ottawa Hospital, Civic Campus	10166	2020-08-20
5369-10 (Participant ID 12-002)	Screening/ Randomization			The Ottawa Hospital, General Campus	10186	2020-09-22
5369-11 (Participant ID 12-003)	Screening/ Randomization			The Ottawa Hospital, General Campus	10173	2020-10-01
5358-141 (Participant ID 01-015)	Screening/ Randomization			Peter Lougheed Centre	10193	2020-10-02
5358-142 (Participant ID 01-016)	Screening/ Randomization			Peter Lougheed Centre	10199	2020-10-14
5358-143 (Participant ID 01-017)	Screening/ Randomization			Peter Lougheed Centre	10205	2020-10-22
5362-118 (Participant ID 05-015)	Screening/ Randomization			South Health Campus	10235	2020-10-24
5358-144 (Participant ID 01-018)	Screening/ Randomization			Peter Lougheed Centre	10206	2020-10-27
5359-16 (Participant ID 02-003)	Screening/ Randomization			University of Maryland Medical Center	10119	2020-10-31
5371-20 (Participant ID 14-001)	Screening/ Randomization			St. Michael's Hospital	10143	2020-11-10
5371-21 (Participant ID 14-002)	Screening/ Randomization			St. Michael's Hospital	10149	2020-11-10
5373-4 (Participant ID 16-001)	Screening/ Randomization			St. Paul's Hospital	20263	2020-11-18
5370-13 (Participant ID 13-008)	Screening/ Randomization			Sturgeon Community Hospital	20326	2020-11-20
5358-154 (Participant ID 01-019)	Screening/ Randomization			Peter Lougheed Centre	10200	2020-11-23
5369-16 (Participant ID 12-004)	Screening/ Randomization			The Ottawa Hospital, General Campus	20317	2020-12-01
5362-131 (Participant ID 05-016)	Screening/ Randomization			South Health Campus	10228	2020-12-15

Screening ID screen_id	**Event Name** redcap_event_name	**Repeat Instrument** redcap_repeat_instrument	**Repeat Instance** redcap_repeat_instance	**Data Access Group** redcap_data_access_group	**BOTTLE ID** rand_group	**Date of randomization** rand_dt
5358-164 (Participant ID 01-020)	Screening/ Randomization			Peter Lougheed Centre	10194	2020-12-29
5373-6 (Participant ID 16-002)	Screening/ Randomization			St. Paul's Hospital	20275	2021-01-13
5362-136 (Participant ID 05-017)	Screening/ Randomization			South Health Campus	10240	2021-01-18
5358-167 (Participant ID 01-021)	Screening/ Randomization			Peter Lougheed Centre	10195	2021-01-19
5362-137 (Participant ID 05-018)	Screening/ Randomization			South Health Campus	10229	2021-01-19
5373-7 (Participant ID 16-003)	Screening/ Randomization			St. Paul's Hospital	20269	2021-01-19
5358-168 (Participant ID 01-022)	Screening/ Randomization			Peter Lougheed Centre	10196	2021-01-20
5370-14 (Participant ID 13-009)	Screening/ Randomization			Sturgeon Community Hospital	20327	2021-01-20
5369-26 (Participant ID 12-005)	Screening/ Randomization			The Ottawa Hospital, General Campus	20318	2021-01-22
5360-29 (Participant ID 03-006)	Screening/ Randomization			Foothills Medical Centre	10220	2021-02-08
5360-30 (Participant ID 03-007)	Screening/ Randomization			Foothills Medical Centre	10214	2021-02-08
5364-1 (Participant ID 07-001)	Screening/ Randomization			Queen Elizabeth II Health Sciences Centre	20351	2021-02-09
5372-1 (Participant ID 15-001)	Screening/ Randomization			Sunnybrook Health Sciences Centre	20358	2021-02-11
5369-28 (Participant ID 12-006)	Screening/ Randomization			The Ottawa Hospital, General Campus	20319	2021-02-12
5370-16 (Participant ID 13-010)	Screening/ Randomization			Sturgeon Community Hospital	20328	2021-03-03
5372-2 (Participant ID 15-002)	Screening/ Randomization			Sunnybrook Health Sciences Centre	20359	2021-03-04
5359-36 (Participant ID 02-004)	Screening/ Randomization			University of Maryland Medical Center	20299	2021-03-05
5360-34 (Participant ID 03-008)	Screening/ Randomization			Foothills Medical Centre	10215	2021-03-08
5360-35 (Participant ID 03-009)	Screening/ Randomization			Foothills Medical Centre	10210	2021-03-09
5364-5 (Participant ID 07-002)	Screening/ Randomization			Queen Elizabeth II Health Sciences Centre	20352	2021-03-11
5362-138 (Participant ID 05-019)	Screening/ Randomization			South Health Campus	10241	2021-03-12
5358-171 (Participant ID 01-023)	Screening/ Randomization			Peter Lougheed Centre	10201	2021-03-14
5374-11 (Participant ID 17-004)	Screening/ Randomization			University of Vermont Medical Center	10258	2021-03-18
5362-141 (Participant ID 05-020)	Screening/ Randomization			South Health Campus	10242	2021-03-24
5359-52 (Participant ID 02-005)	Screening/ Randomization			University of Maryland Medical Center	20300	2021-03-26
5362-143 (Participant ID 05-021)	Screening/ Randomization			South Health Campus	10236	2021-03-31
5370-18 (Participant ID 13-011)	Screening/ Randomization			Sturgeon Community Hospital	20329	2021-04-03
5358-174 (Participant ID 01-024)	Screening/ Randomization			Peter Lougheed Centre	10202	2021-04-07
5359-53 (Participant ID 02-006)	Screening/ Randomization			University of Maryland Medical Center	20301	2021-04-08
5370-21 (Participant ID 13-012)	Screening/ Randomization			Sturgeon Community Hospital	20330	2021-04-09
5360-36 (Participant ID 03-010)	Screening/ Randomization			Foothills Medical Centre	20374	2021-04-19
5374-13 (Participant ID 17-005)	Screening/ Randomization			University of Vermont Medical Center	20392	2021-04-24
5358-175 (Participant ID 01-025)	Screening/ Randomization			Peter Lougheed Centre	20365	2021-05-04

Screening ID screen_id	**Event Name** redcap_event_name	**Repeat Instrument** redcap_repeat_instrument	**Repeat Instance** redcap_repeat_instance	**Data Access Group** redcap_data_access_group	**BOTTLE ID** rand_group	**Date of randomization** rand_dt
5362-144 (Participant ID 05-022)	Screening/ Randomization			South Health Campus	20383	2021-05-06
5370-22 (Participant ID 13-013)	Screening/ Randomization			Sturgeon Community Hospital	20331	2021-05-06
5358-177 (Participant ID 01-026)	Screening/ Randomization			Peter Lougheed Centre	20366	2021-05-07
5372-3 (Participant ID 15-003)	Screening/ Randomization			Peter Lougheed Centre	20360	2021-05-07
5359-54 (Participant ID 02-007)	Screening/ Randomization			University of Maryland Medical Center	20302	2021-05-10
5359-55 (Participant ID 02-008)	Screening/ Randomization			University of Maryland Medical Center	20303	2021-05-11
5360-37 (Participant ID 03-011)	Screening/ Randomization			Foothills Medical Centre	20375	2021-05-17
5359-56 (Participant ID 02-009)	Screening/ Randomization			University of Maryland Medical Center	20304	2021-05-18
5358-179 (Participant ID 01-027)	Screening/ Randomization			Peter Lougheed Centre	20367	2021-05-20
5363-5 (Participant ID 06-001)	Screening/ Randomization			Carolinas Medical Center	20344	2021-05-21
5369-48 (Participant ID 12-007)	Screening/ Randomization			The Ottawa Hospital, General Campus	20320	2021-05-25
5362-147 (Participant ID 05-023)	Screening/ Randomization			South Health Campus	20384	2021-05-28
5373-8 (Participant ID 16-004)	Screening/ Randomization			St. Paul's Hospital	20270	2021-06-02
5360-39 (Participant ID 03-012)	Screening/ Randomization			Sturgeon Community Hospital	20376	2021-06-03
5374-18 (Participant ID 17-006)	Screening/ Randomization			University of Vermont Medical Center	20393	2021-06-05
5374-19 (Participant ID 17-007)	Screening/ Randomization			University of Vermont Medical Center	20394	2021-06-10
5374-20 (Participant ID 17-008)	Screening/ Randomization			University of Vermont Medical Center	20395	2021-06-11
5362-149 (Participant ID 05-024)	Screening/ Randomization			South Health Campus	20385	2021-06-14
5360-41 (Participant ID 03-013)	Screening/ Randomization			Foothills Medical Centre	20377	2021-06-15
5360-44 (Participant ID 03-014)	Screening/ Randomization			Foothills Medical Centre	20378	2021-06-18
5362-151 (Participant ID 05-025)	Screening/ Randomization			South Health Campus	20386	2021-06-18
5370-23 (Participant ID 13-014)	Screening/ Randomization			Sturgeon Community Hospital	20332	2021-06-18
5362-152 (Participant ID 05-026)	Screening/ Randomization			South Health Campus	20387	2021-06-23
5358-180 (Participant ID 01-028)	Screening/ Randomization			Peter Lougheed Centre	20368	2021-06-24
5360-47 (Participant ID 03-015)	Screening/ Randomization			Foothills Medical Centre	20379	2021-06-24
5374-22 (Participant ID 17-009)	Screening/ Randomization			University of Vermont Medical Center	20396	2021-06-25
5374-23 (Participant ID 17-010)	Screening/ Randomization			University of Vermont Medical Center	20397	2021-06-28
5362-153 (Participant ID 05-027)	Screening/ Randomization			South Health Campus	20388	2021-06-29
5370-24 (Participant ID 13-015)	Screening/ Randomization			Sturgeon Community Hospital	20431	2021-07-02
5362-154 (Participant ID 05-028)	Screening/ Randomization			South Health Campus	20389	2021-07-05
5360-49 (Participant ID 03-016)	Screening/ Randomization			Foothills Medical Centre	20380	2021-07-06
5371-23 (Participant ID 14-003)	Screening/ Randomization			St. Michael's Hospital	20437	2021-07-12
5367-2 (Participant ID 10-001)	Screening/ Randomization			Royal Columbian Hospital	20416	2021-07-13

Screening ID screen_id	**Event Name** redcap_event_name	**Repeat Instrument** redcap_repeat_instrument	**Repeat Instance** redcap_repeat_instance	**Data Access Group** redcap_data_access_group	**BOTTLE ID** rand_group	**Date of randomization** rand_dt
5362-158 (Participant ID 05-029)	Screening/ Randomization			South Health Campus	20390	2021-07-15
5362-160 (Participant ID 05-030)	Screening/ Randomization			South Health Campus	20391	2021-07-16
5365-1 (Participant ID 08-001)	Screening/ Randomization			St. Joseph's Hospital	20413	2021-07-16
5367-3 (Participant ID 10-002)	Screening/ Randomization			Royal Columbian Hospital	20417	2021-07-16
5360-56 (Participant ID 03-017)	Screening/ Randomization			Sturgeon Community Hospital	20381	2021-07-20
5359-57 (Participant ID 02-010)	Screening/ Randomization			University of Maryland Medical Center	20398	2021-07-27
5369-63 (Participant ID 12-008)	Screening/ Randomization			The Ottawa Hospital, General Campus	20425	2021-07-27
5364-10 (Participant ID 07-003)	Screening/ Randomization			Queen Elizabeth II Health Sciences Centre	20407	2021-07-28
5362-164 (Participant ID 05-031)	Screening/ Randomization			South Health Campus	20473	2021-08-04
5367-4 (Participant ID 10-003)	Screening/ Randomization			Royal Columbian Hospital	20418	2021-08-06
5367-7 (Participant ID 10-004)	Screening/ Randomization			Royal Columbian Hospital	20419	2021-08-12
5358-184 (Participant ID 01-029)	Screening/ Randomization			Peter Lougheed Centre	20369	2021-08-14
5365-2 (Participant ID 08-002)	Screening/ Randomization			St. Joseph's Hospital	20414	2021-08-17
5367-9 (Participant ID 10-005)	Screening/ Randomization			Royal Columbian Hospital	20420	2021-08-19
5371-24 (Participant ID 14-004)	Screening/ Randomization			St. Michael's Hospital	20438	2021-08-19
5358-186 (Participant ID 01-030)	Screening/ Randomization			Peter Lougheed Centre	20370	2021-08-25
5374-25 (Participant ID 17-011)	Screening/ Randomization			University of Vermont Medical Center	20485	2021-08-25
5360-60 (Participant ID 03-018)	Screening/ Randomization			Foothills Medical Centre	20382	2021-08-27
5362-168 (Participant ID 05-032)	Screening/ Randomization			South Health Campus	20479	2021-08-30
5359-81 (Participant ID 02-011)	Screening/ Randomization			University of Maryland Medical Center	20399	2021-08-31
5362-169 (Participant ID 05-033)	Screening/ Randomization			South Health Campus	20476	2021-09-02
5360-61 (Participant ID 03-019)	Screening/ Randomization			Foothills Medical Centre	20467	2021-09-03
5360-62 (Participant ID 03-020)	Screening/ Randomization			Foothills Medical Centre	20464	2021-09-03
5362-170 (Participant ID 05-034)	Screening/ Randomization			South Health Campus	20477	2021-09-06
5360-63 (Participant ID 03-021)	Screening/ Randomization			Foothills Medical Centre	20470	2021-09-08
5374-27 (Participant ID 17-012)	Screening/ Randomization			University of Vermont Medical Center	20488	2021-09-09
5360-64 (Participant ID 03-022)	Screening/ Randomization			Foothills Medical Centre	20465	2021-09-15
5374-30 (Participant ID 17-013)	Screening/ Randomization			University of Vermont Medical Center	20486	2021-09-16
5372-5 (Participant ID 15-004)	Screening/ Randomization			Sunnybrook Health Sciences Centre	20443	2021-09-17
5362-172 (Participant ID 05-035)	Screening/ Randomization			South Health Campus	20480	2021-09-18
5360-67 (Participant ID 03-023)	Screening/ Randomization			Foothills Medical Centre	20471	2021-09-22
5360-68 (Participant ID 03-024)	Screening/ Randomization			Foothills Medical Centre	20468	2021-09-24
5362-175 (Participant ID 05-036)	Screening/ Randomization			South Health Campus	20474	2021-10-04

Screening ID screen_id	**Event Name** redcap_event_name	**Repeat Instrument** redcap_repeat_instrument	**Repeat Instance** redcap_repeat_instance	**Data Access Group** redcap_data_access_group	**BOTTLE ID** rand_group	**Date of randomization** rand_dt
5367-13 (Participant ID 10-006)	Screening/ Randomization			Royal Columbian Hospital	20421	2021-10-04
5370-26 (Participant ID 13-016)	Screening/ Randomization			Sturgeon Community Hospital	20432	2021-10-05
5363-35 (Participant ID 06-002)	Screening/ Randomization			Carolinas Medical Center	20404	2021-10-06
5374-32 (Participant ID 17-014)	Screening/ Randomization			University of Vermont Medical Center	20489	2021-10-11
5369-73 (Participant ID 12-009)	Screening/ Randomization			The Ottawa Hospital, General Campus	20426	2021-10-14
5367-16 (Participant ID 10-007)	Screening/ Randomization			Royal Columbian Hospital	20505	2021-10-18
5360-69 (Participant ID 03-025)	Screening/ Randomization			Foothills Medical Centre	20466	2021-10-20
5362-178 (Participant ID 05-037)	Screening/ Randomization			South Health Campus	20478	2021-11-04
5371-25 (Participant ID 14-005)	Screening/ Randomization			St. Michael's Hospital	20562	2021-11-04
5358-193 (Participant ID 01-031)	Screening/ Randomization			Sturgeon Community Hospital	20461	2021-11-05
5362-179 (Participant ID 05-038)	Screening/ Randomization			South Health Campus	20475	2021-11-10
5362-180 (Participant ID 05-039)	Screening/ Randomization			South Health Campus	20481	2021-11-10
5360-73 (Participant ID 03-026)	Screening/ Randomization			Foothills Medical Centre	20472	2021-11-16
5365-3 (Participant ID 08-003)	Screening/ Randomization			St. Joseph's Hospital	20496	2021-11-19
5360-74 (Participant ID 03-027)	Screening/ Randomization			Foothills Medical Centre	20469	2021-11-26
5358-195 (Participant ID 01-032)	Screening/ Randomization			Peter Lougheed Centre	20458	2021-12-01
5360-76 (Participant ID 03-028)	Screening/ Randomization			Foothills Medical Centre	20518	2021-12-06
5362-186 (Participant ID 05-040)	Screening/ Randomization			South Health Campus	20530	2021-12-07
5374-37 (Participant ID 17-015)	Screening/ Randomization			University of Vermont Medical Center	20574	2021-12-13
5363-56 (Participant ID 06-003)	Screening/ Randomization			Carolinas Medical Center	20532	2021-12-16
5369-83 (Participant ID 12-010)	Screening/ Randomization			The Ottawa Hospital, General Campus	20547	2021-12-16
5372-6 (Participant ID 15-005)	Screening/ Randomization			Sunnybrook Health Sciences Centre	20568	2021-12-16
5358-197 (Participant ID 01-033)	Screening/ Randomization			Peter Lougheed Centre	20455	2021-12-28
5367-29 (Participant ID 10-008)	Screening/ Randomization			Royal Columbian Hospital	20500	2021-12-29
5358-198 (Participant ID 01-034)	Screening/ Randomization			Peter Lougheed Centre	20462	2021-12-31
5358-199 (Participant ID 01-035)	Screening/ Randomization			Peter Lougheed Centre	20456	2022-01-11
5360-85 (Participant ID 03-029)	Screening/ Randomization			Foothills Medical Centre	20521	2022-01-11
5374-40 (Participant ID 17-016)	Screening/ Randomization			University of Vermont Medical Center	20580	2022-01-13
5373-20 (Participant ID 16-005)	Screening/ Randomization			St. Paul's Hospital	20571	2022-01-14
5358-200 (Participant ID 01-036)	Screening/ Randomization			Peter Lougheed Centre	20459	2022-01-17
5367-33 (Participant ID 10-009)	Screening/ Randomization			Royal Columbian Hospital	20503	2022-01-19
5358-202 (Participant ID 01-037)	Screening/ Randomization			Peter Lougheed Centre	20457	2022-01-21
5358-204 (Participant ID 01-038)	Screening/ Randomization			Peter Lougheed Centre	20463	2022-01-25

Screening ID screen_id	**Event Name** redcap_event_name	**Repeat Instrument** redcap_repeat_instrument	**Repeat Instance** redcap_repeat_instance	**Data Access Group** redcap_data_access_group	**BOTTLE ID** rand_group	**Date of randomization** rand_dt
5362-190 (Participant ID 05-041)	Screening/ Randomization			South Health Campus	20524	2022-01-25
5358-206 (Participant ID 01-039)	Screening/ Randomization			Peter Lougheed Centre	20460	2022-01-26
5373-21 (Participant ID 16-006)	Screening/ Randomization			St. Paul's Hospital	20572	2022-02-02
5362-195 (Participant ID 05-042)	Screening/ Randomization			South Health Campus	20527	2022-02-11
5358-210 (Participant ID 01-040)	Screening/ Randomization			Peter Lougheed Centre	20593	2022-02-16
5364-18 (Participant ID 07-004)	Screening/ Randomization			Queen Elizabeth II Health Sciences Centre	20535	2022-02-17
5367-38 (Participant ID 10-010)	Screening/ Randomization			Royal Columbian Hospital	20501	2022-02-22
5359-86 (Participant ID 02-012)	Screening/ Randomization			University of Maryland Medical Center	20510	2022-02-28
5372-7 (Participant ID 15-006)	Screening/ Randomization			Sunnybrook Health Sciences Centre	20565	2022-02-28
5360-86 (Participant ID 03-030)	Screening/ Randomization			Foothills Medical Centre	20522	2022-03-01
5369-100 (Participant ID 12-011)	Screening/ Randomization			The Ottawa Hospital, General Campus	20545	2022-03-01
5362-197 (Participant ID 05-043)	Screening/ Randomization			South Health Campus	20531	2022-03-07
5374-43 (Participant ID 17-017)	Screening/ Randomization			University of Vermont Medical Center	20577	2022-03-07
5369-101 (Participant ID 12-012)	Screening/ Randomization			The Ottawa Hospital, General Campus	20548	2022-03-08
5360-87 (Participant ID 03-031)	Screening/ Randomization			Foothills Medical Centre	20519	2022-03-11
5358-211 (Participant ID 01-041)	Screening/ Randomization			Peter Lougheed Centre	20590	2022-03-16
5369-103 (Participant ID 12-013)	Screening/ Randomization			The Ottawa Hospital, General Campus	20546	2022-03-16
5358-212 (Participant ID 01-042)	Screening/ Randomization			Peter Lougheed Centre	20594	2022-03-17
5368-86 (Participant ID 11-003)	Screening/ Randomization			The Ottawa Hospital, Civic Campus	20541	2022-03-22
5370-36 (Participant ID 13-017)	Screening/ Randomization			Sturgeon Community Hospital	20554	2022-03-23
5368-88 (Participant ID 11-004)	Screening/ Randomization			The Ottawa Hospital, Civic Campus	20542	2022-03-24
5371-55 (Participant ID 14-006)	Screening/ Randomization			St. Michael's Hospital	20563	2022-03-28
5358-214 (Participant ID 01-043)	Screening/ Randomization			Peter Lougheed Centre	20591	2022-03-29
5363-78 (Participant ID 06-004)	Screening/ Randomization			Carolinas Medical Center	20533	2022-03-30
5360-95 (Participant ID 03-032)	Screening/ Randomization			Foothills Medical Centre	20515	2022-04-02
5359-92 (Participant ID 02-013)	Screening/ Randomization			University of Maryland Medical Center	20512	2022-04-04
5374-44 (Participant ID 17-018)	Screening/ Randomization			University of Vermont Medical Center	20578	2022-04-04
5373-22 (Participant ID 16-007)	Screening/ Randomization			St. Paul's Hospital	20573	2022-04-05
5359-93 (Participant ID 02-014)	Screening/ Randomization			University of Maryland Medical Center	20513	2022-04-12
5374-45 (Participant ID 17-019)	Screening/ Randomization			University of Vermont Medical Center	20581	2022-04-18
5358-215 (Participant ID 01-044)	Screening/ Randomization			Peter Lougheed Centre	20596	2022-04-19
5367-42 (Participant ID 10-011)	Screening/ Randomization			Royal Columbian Hospital	20506	2022-04-21
5373-23 (Participant ID 16-008)	Screening/ Randomization			St. Paul's Hospital	20603	2022-04-28

Screening ID screen_id	**Event Name** redcap_event_name	**Repeat Instrument** redcap_repeat_instrument	**Repeat Instance** redcap_repeat_instance	**Data Access Group** redcap_data_access_group	**BOTTLE ID** rand_group	**Date of randomization** rand_dt
5371-61 (Participant ID 14-007)	Screening/ Randomization			St. Michael's Hospital	20559	2022-05-12
5365-4 (Participant ID 08-004)	Screening/ Randomization			St. Joseph's Hospital	20491	2022-05-13
5371-62 (Participant ID 14-008)	Screening/ Randomization			St. Michael's Hospital	20560	2022-05-19
5367-46 (Participant ID 10-012)	Screening/ Randomization			Royal Columbian Hospital	20507	2022-06-02
5370-40 (Participant ID 13-018)	Screening/ Randomization			Sturgeon Community Hospital	20556	2022-06-03
5372-61 (Participant ID 15-007)	Screening/ Randomization			Sunnybrook Health Sciences Centre	20570	2022-06-08
5359-99 (Participant ID 02-015)	Screening/ Randomization			University of Maryland Medical Center	20509	2022-06-13
5362-206 (Participant ID 05-044)	Screening/ Randomization			South Health Campus	20528	2022-06-14
5365-5 (Participant ID 08-005)	Screening/ Randomization			St. Joseph's Hospital	20494	2022-06-15
5367-52 (Participant ID 10-013)	Screening/ Randomization			Royal Columbian Hospital	20504	2022-06-17
5368-96 (Participant ID 11-005)	Screening/ Randomization			The Ottawa Hospital, Civic Campus	20543	2022-06-17
5371-63 (Participant ID 14-009)	Screening/ Randomization			St. Michael's Hospital	20561	2022-06-20
5374-56 (Participant ID 17-020)	Screening/ Randomization			University of Vermont Medical Center	20575	2022-06-20
5369-120 (Participant ID 12-014)	Screening/ Randomization			The Ottawa Hospital, General Campus	20549	2022-06-21
5358-220 (Participant ID 01-045)	Screening/ Randomization			Peter Lougheed Centre	20595	2022-06-24
5365-6 (Participant ID 08-006)	Screening/ Randomization			St. Joseph's Hospital	20497	2022-06-27
5362-211 (Participant ID 05-045)	Screening/ Randomization			South Health Campus	20583	2022-06-28
5360-99 (Participant ID 03-033)	Screening/ Randomization			Foothills Medical Centre	20516	2022-07-06
5360-100 (Participant ID 03-034)	Screening/ Randomization			Foothills Medical Centre	20520	2022-07-06
5367-54 (Participant ID 10-014)	Screening/ Randomization			Royal Columbian Hospital	20502	2022-07-06
5360-101 (Participant ID 03-035)	Screening/ Randomization			Foothills Medical Centre	20517	2022-07-08
5365-7 (Participant ID 08-007)	Screening/ Randomization			St. Joseph's Hospital	20495	2022-07-08
5360-104 (Participant ID 03-036)	Screening/ Randomization			Foothills Medical Centre	20523	2022-07-15
5358-221 (Participant ID 01-046)	Screening/ Randomization			Peter Lougheed Centre	20592	2022-07-18
5367-58 (Participant ID 10-015)	Screening/ Randomization			Royal Columbian Hospital	20508	2022-07-18
5363-100 (Participant ID 06-005)	Screening/ Randomization			Carolinas Medical Center	20534	2022-07-20
5368-110 (Participant ID 11-006)	Screening/ Randomization			The Ottawa Hospital, Civic Campus	20611	2022-08-03
5359-105 (Participant ID 02-016)	Screening/ Randomization			University of Maryland Medical Center	20514	2022-08-10
5365-8 (Participant ID 08-008)	Screening/ Randomization			St. Joseph's Hospital	20498	2022-08-10
5365-9 (Participant ID 08-009)	Screening/ Randomization			St. Joseph's Hospital	20492	2022-08-10
5360-109 (Participant ID 03-037)	Screening/ Randomization			Foothills Medical Centre	20629	2022-08-11
5374-60 (Participant ID 17-021)	Screening/ Randomization			University of Vermont Medical Center	20576	2022-08-15
5360-112 (Participant ID 03-038)	Screening/ Randomization			Foothills Medical Centre	20630	2022-08-16

Screening ID screen_id	**Event Name** redcap_event_name	**Repeat Instrument** redcap_repeat_instrument	**Repeat Instance** redcap_repeat_instance	**Data Access Group** redcap_data_access_group	**BOTTLE ID** rand_group	**Date of randomization** rand_dt
5362-217 (Participant ID 05-046)	Screening/ Randomization			South Health Campus	20529	2022-08-16
5367-63 (Participant ID 10-016)	Screening/ Randomization			Royal Columbian Hospital	20638	2022-08-22
5372-62 (Participant ID 15-008)	Screening/ Randomization			Sunnybrook Health Sciences Centre	20566	2022-08-23
5370-48 (Participant ID 13-019)	Screening/ Randomization			Sturgeon Community Hospital	20550	2022-08-26
5365-10 (Participant ID 08-010)	Screening/ Randomization			St. Joseph's Hospital	20493	2022-08-30
5363-109 (Participant ID 06-006)	Screening/ Randomization			Carolinas Medical Center	20605	2022-08-31
5372-63 (Participant ID 15-009)	Screening/ Randomization			Sunnybrook Health Sciences Centre	20569	2022-09-01
5358-228 (Participant ID 01-047)	Screening/ Randomization			Peter Lougheed Centre	20597	2022-09-02
5364-32 (Participant ID 07-005)	Screening/ Randomization			Queen Elizabeth II Health Sciences Centre	20539	2022-09-09
5360-123 (Participant ID 03-039)	Screening/ Randomization			Foothills Medical Centre	20631	2022-09-13
5368-122 (Participant ID 11-007)	Screening/ Randomization			The Ottawa Hospital, Civic Campus	20612	2022-09-14
5365-11 (Participant ID 08-011)	Screening/ Randomization			St. Joseph's Hospital	20499	2022-09-15
5368-128 (Participant ID 11-008)	Screening/ Randomization			The Ottawa Hospital, Civic Campus	20613	2022-09-22
5359-115 (Participant ID 02-017)	Screening/ Randomization			University of Maryland Medical Center	20511	2022-09-23
5359-116 (Participant ID 02-018)	Screening/ Randomization			University of Maryland Medical Center	20632	2022-09-26
5367-69 (Participant ID 10-017)	Screening/ Randomization			Royal Columbian Hospital	20639	2022-09-27
5358-232 (Participant ID 01-048)	Screening/ Randomization			Peter Lougheed Centre	20598	2022-09-28

PERK 2 Trial Management Group Meeting #32
July 25th, 2022, 1:00pm-2:00pm MDT

Attendees: Dr. Kevin Hildebrand, Ayoola Ademola, Isabella Salazar, Casey Loudermilk, Chloe Elliot, Christine Churchill, Kelly Trask, Kyrsten Payne, Jennifer Hidy, Sara Aman, Zafeiria Glaris, Melissa Cuke and Gerardo Duque

Regrets: Ethan Patterson, Tosin Ogunleye, Katrina Munro, Melanie Dodd-Moher, Katie McIlquham, and Anelise Silveira

---

Meeting start: 1:00 pm MDT

1. **TMG #32 Report Review**
    - **a.** July continued on the success of screening/recruitment from June for sites
        - **i.** 31 screens with 8 recruited participants overall
    - **b.** AE and SAE reported continue to be within expected patterns
        - **i.** 133 adverse events reported
            1. 103 mild
            2. 22 moderate
            3. 2 severe
        - **ii.** 6 additional AE's from the last report (June 2022)
        - **iii.** Most frequent AE's reported are sedation, nausea/vomiting, and peripheral edema
    - **c.** 253 participants enrolled, with 227 completing baseline assessments
        - **i.** Queries have been updated on data missing or needing review
        - **ii.** **Please review queries within REDcap dashboard**
    - **d.** **Please input up to date data into REDcap so that we are able to review safety and follow up on data issues in real time. This is a Health Canada and FDA expectations for clinical trials**

2. **Centralized Monitoring**
    - **a.** We have completed our first three centralized monitoring visits
    - **b.** Sites will be engaged if it's been 6 months to a year since your initial monitoring visit with Jackie Busheikin from JANA Consulting
    - **c.** Overall we would like to:
        - **i.** Engage sites
        - **ii.** Receive redacted CRF's/source documents for verification with REDCap
        - **iii.** Document findings and opportunities for improvement
        - **iv.** Share and discuss finding with the site and propose courses of action

v. Prepare the site for possible inspections

d. From already completed monitoring visits, we see there is a great opportunity for improvement in documentation practices

e. We will send a report of findings to the site and follow up on resolution of these findings

3. PERK 2: Trial Internal Review

a. PERK 2 went through an internal review/inspection from July 19 to July 25

b. Inspector provided a list of findings for each participating site

c. **Sites will receive an email outlining findings, among other tasks that need to be addressed as soon as possible**

4. July 2022 Tasks

a. Query reports, adverse events, and protocol deviations log requests will go out by Tuesday, August 2nd

b. "Outstanding Credentials" list will be sent to coordinator to update research documents

5. Questions from Site Coordinators

a. "Do all staff members listed in Delegation Log need to update their TCPS to the CORE-2022 version?"

i. TCPS CORE-2022 **will NOT** be needed from participating staff at sites

ii. Only newly added staff will need to complete TCPS CORE-2022 if they have not completed TCPS training in the past

b. "What software do people use to redact documents containing PHI?"

i. Most coordinators have access to the full Adobe Acrobat license through their institutions

ii. "Preview" on Mac computers has a "redact" option that has worked for other coordinators

iii. "Foxit" is another software used by coordinators for safe document redaction. However, there are no trial versions available

Overall Action Items:

- Complete the following:
    - Review queries opened on REDCap and address them to finalize invoices for site payment
    - Update of all surgeon/staff training based on "Outstanding Credentials" document
    - Update AE and SAE Logs, signed and dated by local PI
    - Update protocol deviation and violation logs, and send to us for filing
    - Scheduling of remote monitoring visits

Meeting adjourned 1:25 pm MDT

Next TMG Meeting: Monday, August 29, 2022 at 1:00 pm MDT (12:00pm PDT and 3:00pm EDT)

PERK 2 Trial Management Group Meeting #33
August 29th, 2022, 1:00pm-2:00pm MDT

Attendees: Dr. Kevin Hildebrand, Isabella Salazar, Casey Loudermilk, Tosin Ogunleye, Christine Churchill, Kelly Trask, Kyrsten Payne, Katie McIlquham, Jennifer Hidy, Sara Aman, Zafeiria Glaris, Katrina Munro, Melissa Cuke and Gerardo Duque

Regrets: Ayoola Ademola, Melanie Dodd-Moher, and Anelise Silveira

---

Meeting start: 1:00 pm MDT

1. **TMG #33 Report Review**
    - **a.** August was a very successful screening/recruitment month for sites
        - **i.** 85 screens
        - **ii.** 21 screened were eligible; 11 recruited and 10 unwilling to participate
    - **b.** AE and SAE reported continue to be within expected patterns
        - **i.** 141 adverse events reported
            1. 113 mild
            2. 26 moderate
            3. 2 severe
        - **ii.** 8 additional AE's from the last report (August 2022)
        - **iii.** Most frequent AE's reported are sedation and mild GI issues
    - **c.** 264 participants enrolled, with 245 completing baseline assessments
        - **i.** Queries have been updated on data missing or needing review
        - **ii. Please review queries within REDcap dashboard**
    - **d.** **Please input up to date data into REDcap so that we are able to review safety and follow up on data issues in real time. This is a Health Canada and FDA expectations for clinical trials**

2. **Centralized Monitoring**
    - **a.** We have completed five centralized monitoring visits
    - **b.** Sites will be engaged if it's been 6 months to a year since your initial monitoring visit with Jackie Busheikin from JANA Consulting
    - **c.** Overall we would like to:
        - **i.** Engage sites
        - **ii.** Receive redacted CRF's/source documents for verification with REDCap
        - **iii.** Document findings and opportunities for improvement
        - **iv.** Share and discuss finding with the site and propose courses of action
        - **v.** Prepare the site for possible inspections

d. From already completed monitoring visits, we see there is a great opportunity for improvement in documentation practices

e. We will send a report of findings to the site and follow up on resolution of these findings

3. **Site Payments during September 2022**
    a. Itemized Data Breakdowns (IDB's) will be sent to sites by September 1st, 2022
        i. This document depends on your query responses. You may not receive payment for data that you obtained but have not yet entered into REDcap
    b. Due to upcoming "No Cost Extension" negotiation, you may not receive payments in a timely manner if done after September 28, 2022

4. **PERK 2: Trial Internal Review**
    a. PERK 2 went through an internal review/inspection from July 19 to July 25
    b. Inspector provided a list of findings for each participating site
    c. **Action items need to be addressed as soon as possible. This may affect future trial funding for the site.**

5. **Data Monitoring Committee Letters**
    a. Coordinating centre will be sending out the latest DMC letters to all sites
    b. **Coordinators need to submit these letters to the local REB for documentation**

6. **Update on Protocol #7 Amendment**
    a. Protocol #7 amendment is underway
    b. Documents to be amended include:
        i. Protocol
        ii. Consent Form
        iii. Inclusion/Exclusion **– 7 days change to 10 days for inclusion**

7. **August 2022 Tasks**
    a. Query reports, adverse events, and protocol deviations log requests will go out by Thursday September 1st, 2022
    b. "Outstanding Credentials" list will be sent to coordinator to update research documents

8. **Questions from Site Coordinators**
    a. **"Should we submit the centralized monitoring letters to our local REB's?"**
        i. It is not necessary to submit the findings with your local REB. If you would like to submit to your REB, please reach out to them for confirmation. We can provide further documents, if needed.

<u>Overall Action Items</u>:

- Complete the following:
    - Submit Data Monitoring Committee letters to the local REB for documentation
    - Resolve all queries and data entry so invoices are as updated as possible
    - Submit invoices for site prior to September 28 for timely payment processing
    - Update of all surgeon/staff training based on "Outstanding Credentials" document
    - Update AE and SAE Logs, signed and dated by local PI
    - Update protocol deviation and violation logs, and send to us for filing
    - Scheduling of remote monitoring visits

Meeting adjourned 1:35 pm MDT

Next TMG Meeting: September 26th at 1:00 pm MDT (12:00pm PDT and 3:00pm EDT)

PERK 2 Trial Management Group Meeting #34
September 26th, 2022, 1:00pm-2:00pm MDT

Attendees: Casey Loudermilk, Tosin Ogunleye, Adina Tarcea, Christine Churchill, Kelly Trask, Katrina Munro, Kyrsten Payne, Melanie Dodd-Moher, Katie McIlquham, Jennifer Hidy, Sara Aman, Zafeiria Glaris, Melissa Cuke and Gerardo Duque

Regrets: Dr. Kevin Hildebrand, Isabella Salazar, Ayoola Ademola, and Anelise Silveira

---

Meeting start: 1:00 pm MDT

1. **TMG #34 Report Review**
    - **a.** September continued to be a successful screening/recruitment month for sites
        - **i.** 43 screens
        - **ii.** 15 screened were eligible; 9 recruited and 6 unwilling to participate
    - **b.** AE and SAE reported continue to be within expected patterns
        - **i.** 144 adverse events reported
            1. 116 mild
            2. 26 moderate
            3. 2 severe
        - **ii.** 3 additional AE's from the last report (August 2022)
        - **iii.** Most frequent AE's reported are sedation and mild GI issues
    - **c.** 273 participants enrolled, with 252 completing baseline assessments
        - **i.** Queries have been updated on data missing or needing review
        - **ii. Please review queries within REDcap dashboard**
    - **d.** **Please input up to date data into REDcap so that we are able to review safety and follow up on data issues in real time. This is a Health Canada and FDA expectations for clinical trials**

2. **Site Payments during September 2022**
    - **a.** Itemized Data Breakdowns (IDB's) were sent September 1st
        - **i.** Sites that responded have received updated versions
        - **ii.** Please send us finalized invoices prior to September 30th for payment during October
    - **b.** Due to upcoming "No Cost Extension" negotiations, you may not receive payments in a timely manner if done after September 30

3. **Data Monitoring Committee Letters**
    a. Data Monitoring Committee letters were sent September 1st
    b. Thank you to all sites that have submitted these to your REB already
    c. Sites are able to submit these letters during yearly continuing review

4. **Upcoming Drug Shipments**
    a. Some sites have drug expiring October 19th, 2022
    b. These sites will receive drug shipment prior to this date (~ October 12) to cover enrollments until June, 2023

5. **October 2022 Tasks**
    a. Query reports, adverse events, and protocol deviations log requests will be sent to site building on the email sent to sites on September 1st, 2022
    b. "Outstanding Credentials" list will be sent to coordinator to update research documents
    c. Gerry will be "out of office" from September 28th until October 12th
        i. Please reach out to Isabella Salazar at Isabella.Salazar@ucalgary.ca for any immediate needs

6. **OTA 2022: Meeting with sites**
    a. Isabella Salazar will be attending and would like to meet with fellow PERK 2 coordinators
        i. PERK 2 coordinators attending include:
            1. Melanie Dodd-Moher (TOHC)
            2. Christine Churchill (CMC)
            3. Alicia Alvarez (SHSC)
    b. Hoping to meet with coordinators attending to the COTS meeting
        i. Scheduled for Wednesday, October 12, from 1-5pm at the Tampa Marriott Water Street

Overall Action Items:

- Complete the following:
    - Submit Data Monitoring Committee letters to the local REB for documentation
    - Resolve all queries and data entry so invoices are as updated as possible
    - Submit invoices for site prior to September 29 for timely payment processing
    - Update of all surgeon/staff training based on "Outstanding Credentials" document
    - Update AE and SAE Logs, signed and dated by local PI
    - Update protocol deviation and violation logs, and send to us for filing

Meeting adjourned 1:35 pm MDT

Next TMG Meeting: October 31st at 1:00 pm MDT (12:00pm PDT and 3:00pm EDT)

PERK 2 Trial Steering Committee
Meeting #11
September 12, 2022, 5:30 – 7:00pm MDT

Attendees:
Dr. Nicholas Mohtadi – Chair/Clinical Trialist
Dr. Kevin Hildebrand – Chief Investigator
Dr. Neil White – Site Principal Investigator, South Health Campus
Kelly Trask, BEng, MSc, CCRP – Research Manager, Queen Elizabeth II Health Sciences Centre
Gerardo "Gerry" Duque, MA – Clinical Trials Unit, Facilitator

Regrets:
Dr. Michael Bosse – Sponsor's Medical Expert
Dr. Tolulope Sajobi – Biostatistician

Meeting called to order: 5:30 pm MDT

1. **Trial Steering Committee – Meeting #11 Call to Order**
    a. Meeting #10 minutes approved. No notes or additions requested
    b. No additional agenda items proposed by committee members

2. **Trial Steering Committee Report #11**
    a. AE/SAE change from last report
        i. 15 new adverse events reported during Q4, Year 5
            1. 11 Mild
            2. 4 Moderate
        ii. No serious adverse events reported

    b. PERK 2 – Recruitment through Q4 Year 5 (Jul/Aug/Sep 2022)
        i. 34 of 52 eligible patients recruited. 65% recruitment success rate for the quarter, maintaining a 61% recruitment success rate for the overall trial
        ii. 10 to 12 patients are recruited per month

    c. Primary outcome measure completion (12 week ROM = ~203 out of 212 collected)
        i. 96% of people entered into the trial have primary outcome data
            1. Taking into consideration that some of these have not reached 12 week visit yet

d. New drug procurement and site activity during 2022/2023
    i. New drug batch in production for active sites
    ii. Sites showing difficulties with recruitment will be paused from drug receipt until they address outstanding data entry/collection tasks
        1. St. Joseph Hospital – Working on query responses, data entry, and completion of oversight tasks (i.e. protocol deviation and AE logs)
        2. Carolinas Medical Center – Improvement in recruitment percentages
        3. St. Paul's Hospital – Working on query responses, data entry, and completion of oversight tasks (i.e. protocol deviation and AE logs)
    iii. Data collection/entry is a separate issue from enrollment. Ideally, we would not stop sites from receiving drug if they are doing well in enrollment based on their query resolution/data entry delays

e. Follow up with sites to ensure 12 week ROM data entered
    i. Coordinating center is doing the following:
        1. Sending monthly query reports to sites
        2. Calling coordinator directly to inquire about timelines and data entry
        3. Weekly follow up emails informed from query resolution done through REDCap
        4. Scheduling discussions with PI and Coordinator bring issues to light
        5. Completing Centralized Monitoring visits to establish action items for the site

3. Protocol #7 - Amendments: Sample recalculation & and screening window extension

a. Draft completed and under review by Dr. Sajobi and Ayoola Ademola
b. Final confirmation on changes to efficacy points pending from Dr. Sajobi
    i. Based on previous meeting minutes, changes and confirmation of primary efficacy points will be done by Dr. Hildebrand and Gerry
    ii. Ultimately, we want to make sure the protocol outlines that our primary efficacy point is change in ROM arc flexion-extension at 12 week bilaterally, comparing injured vs healthy elbow
c. Dr. Hildebrand and Gerry will send the final draft of protocol and changes to Dr. Mohtadi
d. After review by TSC chair, draft will be sent to DMC members

4. **2022-2023 No Cost Extension and remaining budget**
    a. No cost extension under review by DoD. Preliminary informal approval confirmed over email. Formal approval is expected to come in after September 15, 2022
    b. DoD approved an advanced payment to the trial of $511K. We expect to invoice for the rest of the money available to the trial by September 2023. We have around $900K US left for the trial
    c. Dr. Hildebrand is reviewing budget to determine enrollment/follow up timelines on remaining budget. Original plan is to recruit until March 2023, but with remaining budget we may be able to extend recruitment until September 2023

Action Items:

- Dr. Hildebrand and Gerry will complete changes of primary efficacy point changes in protocol and then send to Dr. Mohtadi for review
- A final approved draft of protocol amendment will be sent to DMC for final review and approval before submitting to regulatory agencies

Meeting adjourned 6:30 pm MDT

Next TSC meeting: Monday, December 12th, 2022 at 5:30pm – 7:00pm MST

November 26, 2021

From: Dr. James Wright, PERK 2 Data Monitoring Committee (DMC) Chair
To: Dr. Kevin Hildebrand & members of the PERK 2 Trial Steering Committee
Re: DMC Review of the trial "PrEvention of posttraumatic elbow contRactures using Ketotifen 2" – (PERK 2)

Dr. Kevin Hildebrand, PERK 2 principal investigator, and Dr. Nicholas Mohtadi, PERK 2 trial steering committee chair, appointed the DMC, as an independent monitoring entity, to supervise the conduct of this trial. Appointed members of the DMC are all experts in one or more aspects of the subject matter of the trial.

An open meeting was held over teleconference on November 3, 2021. The attendees included:

DMC Members:

- Dr. James Wright, DMC Chair
- Dr. Kim Madden, Trial Methodologist
- Dr. Saam Morshed, Orthopaedic Surgeon/Epidemiologist
- Dr. Helen Razmjou, Advance Practice PT

Investigator:

- Dr. Kevin Hildebrand, PERK 2 Principal Investigator

PERK 2 Staff:

- Dr. Tolulope Sajobi, Biostatistician
- Gerardo Duque, PERK 2 Clinical Trial Unit Facilitator

The following topics were discussed:

- Trial sample size calculation procedures
- Review of current screening/enrollment
- Review of participant data entry status
- Review of participant safety data
- Expectations for future closed meeting

The DMC found that the trial is safe and ethical. No action is needed at the moment; trial can continue as planned.

May this response letter serve to document that this trial is being closely overseen for both safety and efficacy. Please note, that as PI you are responsible for all local IRB reporting. If you have any questions or comments about this DMC response, please contact me.

Regards,

James Wright, CM MD MPH FRCSC FRCS (Ed)
Chief, Economics, Policy & Research
Ontario Medical Association
T – 416.340.2942 / TF – 1.800.268.7215 ext. 2942
150 Bloor St. West, Suite 900, Toronto, ON M5S 3C1

June 7, 2022

From: Dr. James Wright, PERK 2 Data Monitoring Committee (DMC) Chair
To: Dr. Kevin Hildebrand & members of the PERK 2 Trial Steering Committee
Re: DMC Review of the trial "PrEvention of posttraumatic elbow contRactures using Ketotifen 2" – (PERK 2)

Dr. Kevin Hildebrand, PERK 2 principal investigator, and Dr. Nicholas Mohtadi, PERK 2 trial steering committee chair, appointed the DMC, as an independent monitoring entity, to supervise the conduct of this trial. Appointed members of the DMC are all experts in one or more aspects of the subject matter of the trial.

A **closed meeting** was held over teleconference on **May 30, 2022**. The attendees included:

DMC Members:

- Dr. James Wright, DMC Chair
- Dr. Kim Madden, Trial Methodologist
- Dr. Saam Morshed, Orthopaedic Surgeon/Epidemiologist
- Dr. Helen Razmjou, Advance Practice PT

Independent Statisticians from EPICORE:

- Dr. Yazid Al-Hamarneh
- Dr. Benjamin Vandermeer
- Mr. Bo Pan

The independent statistics team provided a closed report with data separated by groups. The groups were blinded to the treatment they represented. After review, DMC determined unnecessary to unblind the groups in the report.

Further, the following topics were discussed:

- Review of demographic variables by treatment group
- Review of efficacy endpoints by treatment group
- Review of safety endpoints by treatment group
- Recommendations on best reporting practices for future analyses

The DMC found that the trial continues to be safe and ethical. No action is needed at the moment; **trial can continue as planned**.

May this response letter serve to document that this trial is being closely overseen for both safety and efficacy. Please note, that as PI you are responsible for all local IRB reporting. If you have any questions or comments about this DMC response, please contact me.

Regards,

James Wright, CM MD MPH FRCSC FRCS (Ed)
Chief, Economics, Policy & Research
Ontario Medical Association
T – 416.340.2942 / TF – 1.800.268.7215 ext. 2942
150 Bloor St. West, Suite 900, Toronto, ON M5S 3C1

PERK 2 TRIAL NEWSLETTER

Dr. Kevin A. Hildebrand

July 2022 Edition

PERK 2

GOALS

By July 31:

- Reach 260 total recruitments for the trial
- Complete pharmacy/participant payments for active sites
- Complete query resolution at sites

MILESTONES

Current Overall Enrollment Status:

Peter Lougheed Centre (n=45)
South Health Campus (n=45)
Foothills Medical Centre (n=32)
University of Vermont Medical Center (n=20)
Sturgeon Community Hospital (n=18)
University of Maryland Medical Center (n=15)
The Ottawa Hospital, General Campus (n=14)
Royal Columbian Hospital (n=13)
St. Michael's Hospital (n=9)
St. Paul's Hospital (n=8)
Sunnybrook HSC (n=7)
St. Joseph's Hospital (n=6)
The Ottawa Hospital, Civic Campus (n=5)
Queen Elizabeth II HSC (n=4)
Carolinas Medical Center (n=4)

June 2022 Enrollment Hall of Fame:

1. Royal Columbian Hospital (n=2)
2. South Health Campus (n=2)
3. St. Joseph's Hospital (n=2)
4. Peter Lougheed Centre (n=1)
5. Sturgeon Community Hospital (n=1)
6. Sunnybrook HSC (n=1)
7. University of Maryland (n=1)
8. The Ottawa, Civic (n=1)
9. The Ottawa, General (n=1)
10. University of Vermont (n=1)
11. St. Michael's Hospital (n=1)



TRIAL UPDATES

- With **14 participants** enrolled in **June**, we have reached 245 participants!
- We have updated queries at all sites. Please address all queries as soon as possible to complete latest payments, and data completion tasks.
- The next **Trial Management Group** meeting with active sites proposed for **Monday, July 25, 2022 at 1:00pm MDT (12:00pm PDT, 3:00pm EDT)**.

PERK 2 TEAM

Trial PI/Sponsor:	Kevin Hildebrand	403-220-7282
Research Coordinator:	Gerardo Duque	403-943-5556
Research Assistant:	Isabella Salazar	403-943-5537

PERK 2 TRIAL NEWSLETTER

Dr. Kevin A. Hildebrand

August 2022 Edition

PERK 2

GOALS

By August 31:

- Reach 270 total recruitments for the trial
- Complete pharmacy/participant payments for active sites
- Complete query resolution at sites

MILESTONES

Current Overall Enrollment Status:

Peter Lougheed Centre (n=46)
South Health Campus (n=45)
Foothills Medical Centre (n=36)
University of Vermont Medical Center (n=20)
Sturgeon Community Hospital (n=18)
University of Maryland Medical Center (n=15)
Royal Columbian Hospital (n=15)
The Ottawa Hospital, General Campus (n=14)
St. Michael's Hospital (n=9)
St. Paul's Hospital (n=8)
Sunnybrook HSC (n=7)
St. Joseph's Hospital (n=7)
The Ottawa Hospital, Civic Campus (n=5)
Carolinas Medical Center (n=5)
Queen Elizabeth II HSC (n=4)

July 2022 Enrollment Hall of Fame:

1. Foothills Medical Centre (n=4)
2. Royal Columbian Hospital (n=2)
3. Peter Lougheed Centre (n=1)
4. Carolinas Medical Center (n=1)



TRIAL UPDATES

- With **8 participants** enrolled in **July**, we have reached 254 participants!
- Updated query report and AE/Protocol Deviation logs needed from sites. In addition, site findings from recent trial internal review will be sent to sites in early August.
- The next **Trial Management Group** meeting with active sites proposed for **Monday, August 29, 2022 at 1:00pm MDT (12:00pm PDT, 3:00pm EDT)**.

PERK 2 TEAM

Trial PI/Sponsor:	Kevin Hildebrand	403-220-7282
Research Coordinator:	Gerardo Duque	403-943-5556
Research Assistant:	Isabella Salazar	403-943-5537

PERK 2 TRIAL NEWSLETTER

Dr. Kevin A. Hildebrand

September 2022 Edition

GOALS

By September 30:

- Reach 285 total recruitments for the trial
- Complete pharmacy/participant payments for active sites
- Complete query resolution at sites

MILESTONES

Current Overall Enrollment Status:

Peter Lougheed Centre (n=46)
South Health Campus (n=46)
Foothills Medical Centre (n=38)
University of Vermont Medical Center (n=21)
Sturgeon Community Hospital (n=19)
University of Maryland Medical Center (n=16)
Royal Columbian Hospital (n=16)
The Ottawa Hospital, General Campus (n=14)
St. Joseph's Hospital (n=10)
St. Michael's Hospital (n=9)
St. Paul's Hospital (n=8)
Sunnybrook HSC (n=8)
The Ottawa Hospital, Civic Campus (n=6)
Carolinas Medical Center (n=6)
Queen Elizabeth II HSC (n=4)

August 2022 Enrollment Hall of Fame:

1. St. Joseph's Hospital (n=3)
2. Foothills Medical Centre (n=2)
3. Sturgeon Community Hospital (n=1)
4. Sunnybrook HSC (n=1)
5. Royal Columbian Hospital (n=1)
6. South Health Campus (n=1)
7. University of Vermont MC (n=1)
8. University of Maryland MC (n=1)
9. Carolinas Medical Center (n=1)
10. The Ottawa Hospital, Civic (n=1)



TRIAL UPDATES

- With **13 participants** enrolled in **August**, we have reached 267 participants!
- Please resolve outstanding queries and review Itemized Data Breakdown (IDB) sent to your site to finalize updated invoices. To receive payments, invoices need to be done by September 15, 2022
- The next **Trial Management Group** meeting with active sites proposed for **Monday, September 26, 2022 at 1:00pm MDT (12:00pm PDT, 3:00pm EDT)**.

PERK 2 TEAM

Trial PI/Sponsor:	Kevin Hildebrand	403-220-7282
Research Coordinator:	Gerardo Duque	403-943-5556
Research Assistant:	Isabella Salazar	403-943-5537

From: registrations@isoqualitytesting.com
To: Gerardo Duque
Subject: Score Report
Date: Thursday, September 22, 2022 4:38:48 PM

[EXTERNAL]

SCORE REPORT

Society of Clinical Research Associates
Certified Clinical Research Professional (CCRP®) Exam

Duque Boos, Gerardo
c/o Gerardo A Duque Boos 1177-408 11th Ave SW
Calgary AB T2R 1K9

Candidate ID Number: 74568

Examination Date: 9/22/2022

Exam Result: PASS

Congratulations on your achievement! You have achieved a passing score on the SOCRA Clinical Research Professional Certification Examination (CCRP®). You may now use the CCRP® designation. You will receive your official certificate and information regarding maintenance of certification in a few weeks.

For more information on the scoring of your exam and recertification (e.g., continuing education requirements, etc.) please visit the certification section of www.socra.org.

For information on membership, please visit the membership section of www.socra.org.